Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel

Journal of Drugs in Dermatology

Volumn 13, Issue 6, 2014, Pages 685-688

  Leyden, James J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYL PEROXIDE; SILICON DIOXIDE; DERMATOLOGICAL AGENT; GEL;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENCAPSULATION; FEMALE; GEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MICROCAPSULE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; ROSACEA; AGED; CHEMISTRY; CLINICAL TRIAL; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; BENZOYL PEROXIDE; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GELS; HUMANS; MALE; MIDDLE AGED; ROSACEA; SEVERITY OF ILLNESS INDEX; SILICON DIOXIDE; TREATMENT OUTCOME;

EID: 84903382655     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Powell FC. The histopathology of rosacea: 'where's the beef?'. Dermatology. 2004;209:173-174.
2. Powell FC. Rosacea and the pilosebaceous follicle. Cutis. 2004;74:9-12, 32-4. Review.
3. Steinhoff M, Buddenkotle J, Aubert J et al. Clinical, cellular and molecular aspects in the pathophysiology of rosacea. J Inves. Derm 2011;15:2-11.
4. Yamasaki K, Gallo R. Rosacea as a disease of cathelicidious and skin innate immunity. J Invest Derm. 2011;15:12-15.
5. Schwab VD, Sulk M, Seeliger S et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Invest Dermatol Symp Proc. 2011;15:53-62.
6. Forton FMN. Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing link. J Eur Acad Dermatol Venereol. 2012;26:19-28.
7. Elewski BE, Fleischer AB Jr, Pariser DM et al. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-50. (Pubitemid 37433134)
8. Wolf JE Jr, Del Rosso JQ. The CLEAR trial: results of a large communitybased study of metronidazole gel in rosacea. Cutis. 2007;79:73-80.
9. Del Rosso JQ, Webster GF, Jackson M et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791-802. (Pubitemid 46561002)
10. Breneman D, Savin R, VandePol C et al. Double-blind, randomized, vehiclecontrolled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43:381-7. (Pubitemid 38714606)
11. Gold M, Farber H, Gilboa R, Tschen E. Use of benzoyl peroxide/clindamycin gel in the once daily treatment of moderate rosacea. Poster presented at 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, LA P161.
12. Toledano O, Abu-Reziq R, Bar-Simantov H, Bilman N, Sertchook H, Shapiro L, Sommer WT, Sriadibhatla S. Method for Preparing Particles Comprising Metal Oxide Coating and Particles with Metal Oxide Coating. Published Patent Application WO 2008/093347 (2008).
13. Toledano O, Mavor D, Drori E, Hershkovitch S, Erlich M. Topical Compositions Containing Coated Active Agents. Published Patent Application WO 2010/076803 (2010).
14. O'Reilly N, Bergin D, Reeves EP, McElvaney NG, Kavanagh K. Demodex-Associated Bacterial Proteins Induce Neutrophil Activation. Brit J Dermatol. 2012;166, 753-760.